Search PubMed⌕ Search

Biomedical subjects

W Queisser

Publications and source records attributed to W Queisser.

At least 55 records · Page 3Linked to original sources
PubMed1988

Megakaryocyte polyploidy and maturation in chronic granulocytic leukemia.

To understand abnormal platelet production in chronic granulocytic leukemia, polyploidization and maturation of megakaryocytes in 10 patients were studied using a technique which allows sequential immunofluorescence identification by a monoclonal platelet antibody (C17), cytophotometric determination of the relative DNA content and cytological characterization of megakaryocytes in panoptically stained smears. Compared to normal conditions the proportion of diploid promegakaryocytes was not increased, suggesting an undisturbed influx of progenitor cells into the megakaryocytic cell compartment. Small tetraploid (4c) megakaryocytes undergo maturation without further polyploidization, the so-called microkaryocytes being mature rather than immature cells. Most of the megakaryocytes show rhythmical polyploidization only up to octoploid (8c) level, indicating the inability to produce high-polyploidy cells.

Adult↗
PubMed1988

[Induction and intensive combined therapy of acute myeloid leukemia in adults].

In a prospective multicenter study the efficacy and toxicity of an induction therapy with daunorubicin, cytosine-arabinoside and VP 16-213, followed by an intensified consolidation with high-dose cytosine-arabinoside and daunorubicin, is evaluated in adult patients with acute myelogenous leukemia. The upper age limit for inclusion in the study was 50 years. Within the first two years of this study 91 patients were enrolled. In 84 patients who have finished the remission induction therapy the rate of complete remissions is 67%. The median survival time of all patients is 22 months and the probability of survival is 46% after 24 months. So far 34 patients in complete remission have been given one or two courses of the intensified consolidation therapy with high-dose cytosine-arabinoside and daunorubicin. The probability of relapse-free survival in these patients is 46% after 22 months and the median remission duration is 20 months.

Adolescent↗
PubMed1988

[Hepatotoxicity with etoposide-ifosfamide combination therapy].

Combination chemotherapy with etoposide and ifosfamide in 2 patients with advanced bronchial carcinomas caused hepatotoxic side effects. Hepatotoxicity was observed during and immediately after the 5-day therapy and was characterised by a massive rise in direct bilirubin, drop in cholinesterase, as well as a rise in the alkaline phosphatase and to a lesser extent in gGT and GOT. Hepatotoxicity was lethal in one case and reversed to normal in the other. Hepatotoxicity was most likely caused by ifosfamide, since this drug was applied for the first time in both cases. Nonetheless, a contribution of etoposide in this regard can not be excluded since there were liver enzyme alterations in one case after a previous course of chemotherapy using etoposide and cis-platinum.

Aged↗
PubMed1987

Diploid and tetraploid precursors of megakaryocytes in normal human bone marrow detected by immunofluorescence.

A sequential preparation method is described which allows immunological identification, morphological characterization, cytophotometric determination of relative DNA content of the megakaryocyte lineage as well as quantitation of megakaryocyte precursors in human bone marrow aspirates. We compared several monoclonal (anti-GP IIIa and HD 19) and polyclonal (A225, RAHPS) antiplatelet antibodies for immunofluorescent staining. Among the identified cells, a small number of cells showing a diploid and tetraploid DNA content were found which must be regarded as promegakaryoblasts, representing 2.5-4.7% of all megakaryocytes. The heterogenous morphology of these precursors in panoptically stained smears is described.

Bone Marrow Cells↗
PubMed1987

[Prospective controlled study of therapy of chronic myeloid leukemia (CML)].

The current status of the prospective German multicenter study on the therapy of chronic myelogenous leukemia (CML) is reported. After three years 188 of the projected 300 patients have been randomized. The duration of the study will be 8 years. The clinical characteristics of the randomized patients correspond well to those reported in the literature. Risk factors are distributed equally in both arms. One problem is the relatively high drop-out rate of about 12% thus far. Survival curves for the two treatment arms will be presented, although at present the number of patients having reached the end of the chronic phase is too small to allow definitive evaluation.

Adult↗
PubMed1987

5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".

In a phase-II-trial 40 patients with advanced gastric cancer were treated with 5-fluorouracil, 4-epidoxorubicin, mitomycin C (FEM) combination therapy. Twenty-five out of 30 patients with measurable disease were evaluable for response after 8 weeks of treatment. Seven patients achieved a partial remission (PR), suggesting a response rate of 28%. Ten patients had no change (NC) and 8 patients showed progression (P). The median time to progression for patients with PR was 7.2 months and for patients with NC 6.3 months. Median survival time for all patients was 5.3 months, for patients with PR and NC 9.9 months. WHO grade 3 toxicity appeared in 3% (WBC and nausea/vomiting) and 15% (alopecia) of patients. The data suggest that this regimen is not more active, but is better tolerated than the original FAM schedule. Therefore it seems suitable for out-patient treatment, for elderly patients and for those who cannot be treated by more aggressive drugs.

Aged↗
PubMed1986

[Carcinoid].

Explore the source record for details and available documents.

Aged↗
PubMed1986

Prognostic factors of advanced colorectal cancer patients.

The cooperative oncology group for Chemotherapy of Gastrointestinal Tumors (CGT) retrospectively examined 139 patients with metastatic colorectal cancer for prognostic factors. Clinical characteristics, tumor parameters, and blood parameters were investigated for prognostic explanation of survival from the start of chemotherapy for the advanced disease. A combination of a univariate regression and a multivariate step down procedure with Cox's regression model led to the identification of performance status, sex, white blood count and, to a lesser degree, blood sedimentation rate and albumin as important prognostic factors. Based on these variables an individual risk score was calculated for each patient.

Colombia↗
PubMed1986

[Quality of life of cancer patients under chemo- and radiotherapy. Prospective study of patients with gastrointestinal and bronchial cancers].

In a prospective study, 156 patients with advanced lung and gastrointestinal carcinomas, receiving palliative chemotherapy or radiotherapy, were examined for changes in their quality of life during therapy. A questionnaire (68 questions), a linear analogue scale, and the Karnofsky performance scale were used three times in the course of therapy. The most important result seen during the evaluation of the questionnaire was the improvement in the psychical state in patients with tumor remission, even with increasing side-effects. In patients with progressive disease, a deteriorated psychosocial state and an increased burden due to the toxic side effects were observed. These results were also confirmed in progressive patients by the linear analogue scale. The Karnofsky performance scale showed a high correlation for the judgement of disease-related contents and the activity of the patient. In this study the relationship of treatment results and well-being is shown. It would seem important to include methods for the measurement of quality of life for the evaluation of oncological therapies.

Carcinoma, Bronchogenic↗